Introduction:What they say:
A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer Science with an impact factor of 19+) by Prof Andrea L. Cox, Park BV and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based PD-1 pathway blockade for Human cancer therapy: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce, inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene
What is known?
It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.
What we say: Research Findings:
This study suggests a natural product-based Human cancer therapy.
I had shown earlier that Isorhapontigenin may:(1) prolong mammalian life span via down-regulation of angiotensin II type I receptor and p70 S6 Kinase and up-regulation of BuBR1; (2) promote reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up-regulation of Ngn3; and (3) and inhibit the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3.
Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce , among others, suppresses the expression of PD-1 and augments anti-tumor immunity
Isorhapontigenin
Norway Spruce
Sitka spruce. Sitka spruce extract slows down aging and increases median lifespan via up-regulation of BuBR1
White spruce (Picea glauca)
The study presented here suggests that Isorhapontigenin, by decreasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may (1) increase the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes; (2) augment anti-tumor activity of the immune system; & (3) inhibit metastatic cancer progression.
Therapeutic opportunity:
Given that Natural product Isorhapontigenin has a number of favorable pharmacological health benefits, as discussed above, to human health, it may be a drug candidate of choice for cancer prevention. Thus, pharmacological formulations encompassing “Isorhapontigenin or its analogs” may be used to inhibit the progression of tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., Natural product-based PD-1 pathway blockade for Human cancer therapy: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce, inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 27/october/2016, 8.18 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org or http://newbioideas.com
Courtesy: When you cite drop us a line at info@genomediscovery.org
# Research cooperation
Amount: $500
Undisclosed information: How Isorhapontigenin suppresses the expression of PD-1 and augments anti-tumor immunity
Results guaranteed if not refunded